Antibody therapeutics represents a major breakthrough in combating human diseases including cancer. Even though the pharmaceutical and biotechnology industries are in the center stage of drug discovery and development, academic researchers are increasingly engaged in discovering new antibody drug candidates. However, advancing some of the promising antibodies in the early stage of discovery from academic research laboratories is often hindered by the lack of access to the expertise and infrastructure required for antibody lead optimization. Our antibody engineering and expression core will fill the gap of the much needed expertise for advancement of monoclonal antibodies from early discovery to lead optimization and preclinical development for the research and drug discovery communities.